Tyler McConville: Why Hemostatic Function Matters More Than Cell Counts in Trauma and Transfusion
Tyler McConville, Deputy CEO at Sangtech Lab, shared a post on LinkedIn:
“A platelet count is not a hemostatic capacity.
As a blood filtration company In trauma and transfusion, we lean on a single number because it’s fast and it’s everywhere.
But the evidence is hard to ignore.
Kutcher et al. found 45.5% of trauma patients were platelet-hypofunctional on arrival despite normal counts (J Trauma Acute Care Surg, 2012).
Wohlauer et al. measured a median 86.1% inhibition of ADP-stimulated platelet function in patients whose counts looked fine (J Am Coll Surg, 2012).
Reduced clot strength on viscoelastic testing predicts 30-day mortality even when the count is in range (Nystrup et al., 2011).’
Plasma is no different.
It isn’t volume that stops bleeding, it’s functional factors, fibrinogen first among them, where low functional fibrinogen predicts the need for massive transfusion (Schöchl et al., Critical Care, 2011).
As a blood filtration company, we have to consider the impact on the whole blood we process, to ensure we preserve this capacity of the source blood products.
‘Acute hemostatic capacity, which is better preserved with cold storage, is a more relevant measure of function in patients with severe bleeding and at high risk of death within hours than the ability of the PLTs to circulate for days.’ (Spinella et al., Transfusion, 2016).
This is why we build the way we build. It’s easy to design a process that protects the numbers.
It’s harder, and it matters far more, to protect what those cells and factors actually do when a patient is bleeding out.
Filter, store, or process blood while quietly degrading its function, and you’ve shipped something that looks right on paper and fails at the most critical moment.
That’s the line we hold ourselves to.
Count tells you how many.
Function tells you whether they’ll work.”
Stay updated with Hemostasis Today.
-
Nov 20, 2026, 11:28Stéphanie Forté: Bringing Cutting-Edge Genomic and Proteomic Tools to Sickle Cell Disease Patients
-
Nov 20, 2026, 11:19EHC Urges Equal Early Diagnosis for Bleeding Disorders
-
Nov 20, 2026, 11:14Pushpinder Singh: How Do We Know if Haemodialysis is Effective?
-
Nov 20, 2026, 11:09Neel Patel: Hematocon 2026 – Advancing Hematology Through Knowledge, Collaboration and Innovation
-
Nov 20, 2026, 11:03Alok Khorana: First FXI Inhibitor Approved in the US
-
Nov 20, 2026, 06:51How YERM Shapes the Careers of Future Hematology Researchers – EHA
-
Nov 20, 2026, 06:44Ann Van De Velde: Emerging Advances in Hemoglobinopathies, Sickle Cell Disease and Rare Anemias
-
Nov 20, 2026, 06:29Markus Müller: ABO Blood Groups and the Rare Bombay Phenotype
-
Nov 20, 2026, 05:57Lance Reed: Specialized Blood Components and Clinical Samples for Research and Diagnostics